Where is Incyte Corporation (INCY) Headed According to Analysts?

Group 1 - Incyte Corporation (NASDAQ:INCY) is recognized as a strong immunotherapy stock by hedge funds, with multiple firms reiterating Buy ratings and raising price targets [1][2][3] - Jefferies set a price target of $120, while Morgan Stanley increased its target to $102 from $94, maintaining an Equal Weight rating [1] - Stifel also raised its price target to $120 from $119, maintaining a Buy rating, while noting a "quiet(ish)" first half but positive long-term outlook [2] Group 2 - Incyte reported Q4 and full-year financial results for 2025, with total revenue of $1.51 billion for the quarter, a 28% increase year-over-year [3] - Full-year revenue reached $5.14 billion, reflecting a 21% growth compared to the previous year, driven by increases in net product revenue and milestone and contract revenue [3] Group 3 - Incyte is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in oncology, hematology, inflammation, and autoimmunity [4]